Glucocorticoid Receptor Polymorphisms and Intraocular Pressure Response to Intravitreal Triamcinolone Acetonide

Background: Elevation of intraocular pressure (IOP) following injection of intravitreal triamcinolone acetonide (IVTA) is an important clinical problem. The etiology of the steroid response is poorly understood, although a genetic determinant has long been suspected. We performed a pharmacogenomic association study with glucocorticoid receptor polymorphisms. Materials and Methods: Fifty-two patients (56 eyes) who underwent treatment with IVTA for various retinal diseases were genotyped for six well-studied glucocorticoid receptor polymorphisms (ER22/23EK, N363S, BclI, N766N, and single nucleotide polymorphisms (SNPs) within introns 3 and 4). Results: Three polymorphisms (ER22/23EK, N363S, and the intron 3 SNP) were essentially nonpolymorphic within this population sample and excluded from further analysis. The remaining three polymorphisms (BclI, N766N, and within intron 4) passed the Hardy-Weinberg Equilibrium test, indicating good genotyping quality and normal population distribution of allelic frequency. No statistically significant correlations were found between these three polymorphisms and magnitude of IOP elevation following IVTA, using single point association and haplotype analyses. Conclusions: In this small, pilot study, we found no statistically significant relationship between glucocorticoid receptor polymorphisms and IOP elevation following IVTA. The precise etiology of the steroid response remains obscure. To our knowledge, this is the first published pharmacogenomic study of this common clinical entity.

[1]  M. Fini,et al.  Pharmacogenomics of Open-Angle Glaucoma , 2008 .

[2]  L. Katz.  Association between Genetic Polymorphisms of the Prostaglandin F2α Receptor Gene and Response to Latanoprost , 2008 .

[3]  P. Kaiser,et al.  Adverse events after intravitreal triamcinolone in patients with and without uveitis. , 2007, Ophthalmology.

[4]  N. Prasad,et al.  Evaluation of patient age as a risk factor for intraocular pressure elevation after intravitreal triamcinolone. , 2007, American journal of ophthalmology.

[5]  M. Bissell.  β1-Adrenergic Receptor Polymorphisms and Clinical Efficacy of Betaxolol Hydrochloride in Normal VolunteersSchwartz SG, Puckett BJ, Allen RC, et al (Univ of Miami, Fla; Virginia Commonwealth Univ, Richmond) Ophthalmology 112:2131–2136, 2005§ , 2007 .

[6]  J. Chang,et al.  Intraocular pressure alterations following intravitreal triamcinolone acetonide , 2006, British Journal of Ophthalmology.

[7]  S. Schwartz,et al.  Severe steroid-induced glaucoma following intravitreal injection of triamcinolone acetonide. , 2006, American journal of ophthalmology.

[8]  T. Yorio,et al.  Heat Shock Protein 90 Is an Essential Molecular Chaperone for Nuclear Transport of Glucocorticoid Receptor β , 2006 .

[9]  T. Yorio,et al.  Heat shock protein 90 is an essential molecular chaperone for nuclear transport of glucocorticoid receptor beta. , 2006, Investigative ophthalmology & visual science.

[10]  G. Staurenghi,et al.  Argon laser trabeculoplasty for intractable glaucoma following intravitreal triamcinolone. , 2006, Archives of ophthalmology.

[11]  W. Tissing,et al.  Genetic Variations in the Glucocorticoid Receptor Gene Are Not Related to Glucocorticoid Resistance in Childhood Acute Lymphoblastic Leukemia , 2005, Clinical Cancer Research.

[12]  J. Sorenson,et al.  Photodynamic therapy with verteporfin combined with intravitreal injection of triamcinolone acetonide for choroidal neovascularization. , 2005, Ophthalmology.

[13]  Michael D. Ober,et al.  Intravitreal triamcinolone acetonide and intraocular pressure. , 2004, American journal of ophthalmology.

[14]  C. Puliafito,et al.  Intravitreal triamcinolone for the treatment of macular edema associated with central retinal vein occlusion. , 2004, Archives of ophthalmology.

[15]  F. Kuhn,et al.  Intravitreal injection of triamcinolone acetonide for diabetic macular edema. , 2004, Archives of ophthalmology.

[16]  Vishali Gupta,et al.  Intractable glaucoma following intravitreal triamcinolone in central retinal vein occlusion. , 2004, American journal of ophthalmology.

[17]  A. Uitterlinden,et al.  Identification of the BclI polymorphism in the glucocorticoid receptor gene: association with sensitivity to glucocorticoids in vivo and body mass index , 2003, Clinical endocrinology.

[18]  S. Moroi,et al.  Clinical implications of pharmacogenetics for glaucoma therapeutics , 2003, The Pharmacogenomics Journal.

[19]  A. Uitterlinden,et al.  A polymorphism in the glucocorticoid receptor gene, which decreases sensitivity to glucocorticoids in vivo, is associated with low insulin and cholesterol levels. , 2002, Diabetes.

[20]  J. Duker,et al.  Intravitreal triamcinolone for refractory diabetic macular edema. , 2002, Ophthalmology.

[21]  D. Grobbee,et al.  A polymorphism in the glucocorticoid receptor gene may be associated with and increased sensitivity to glucocorticoids in vivo. , 1998, The Journal of clinical endocrinology and metabolism.

[22]  D. Grobbee,et al.  Lack of association between five polymorphisms in the human glucocorticoid receptor gene and glucocorticoid resistance , 1997, Human Genetics.

[23]  R. Weinreb,et al.  Detection of glucocorticoid receptors in cultured human trabecular cells. , 1981, Investigative ophthalmology & visual science.

[24]  D. Shin,et al.  HLA antigens and corticosteroid response. , 1976, Science.

[25]  J. Wilensky,et al.  The reproducibility of the intraocular pressure response to dexamethasone. , 1975, American journal of ophthalmology.

[26]  B. Becker,et al.  INTRAOCULAR PRESSURE RESPONSE TO TOPICAL CORTICOSTEROIDS. , 1965, Investigative ophthalmology.